Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.90 | 0.00% | 0.00 |
CRVS closed unchanged on Monday, March 18, 2024, on 80 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 26
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 200 DMA | Bearish | 1.06% | |
Lower Bollinger Band Walk | Weakness | 1.06% | |
Below Lower BB | Weakness | 1.06% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 17 hours ago |
Possible NR7 | about 19 hours ago |
200 DMA Resistance | about 23 hours ago |
Rose Above Previous Day's High | about 23 hours ago |
Rose Above 200 DMA | about 23 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/26/2024
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.19 |
52 Week Low | 0.607 |
Average Volume | 204,022 |
200-Day Moving Average | 1.98 |
50-Day Moving Average | 2.14 |
20-Day Moving Average | 2.16 |
10-Day Moving Average | 2.04 |
Average True Range | 0.16 |
RSI (14) | 37.11 |
ADX | 28.05 |
+DI | 13.66 |
-DI | 22.60 |
Chandelier Exit (Long, 3 ATRs) | 1.96 |
Chandelier Exit (Short, 3 ATRs) | 2.30 |
Upper Bollinger Bands | 2.47 |
Lower Bollinger Band | 1.85 |
Percent B (%b) | 0.09 |
BandWidth | 28.99 |
MACD Line | -0.06 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0447 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.05 | ||||
Resistance 3 (R3) | 2.07 | 2.03 | 2.03 | ||
Resistance 2 (R2) | 2.03 | 2.00 | 2.03 | 2.02 | |
Resistance 1 (R1) | 1.97 | 1.97 | 1.95 | 1.95 | 2.01 |
Pivot Point | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 |
Support 1 (S1) | 1.87 | 1.90 | 1.85 | 1.85 | 1.79 |
Support 2 (S2) | 1.83 | 1.87 | 1.83 | 1.78 | |
Support 3 (S3) | 1.77 | 1.83 | 1.78 | ||
Support 4 (S4) | 1.75 |